RetinalGeniX Technologies Inc

As of June 30, 2026, RetinalGeniX Technologies Inc carries a market capitalization of 75.37M, placing it among publicly traded companies globally. Its enterprise value stands at 75.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, RetinalGeniX Technologies Inc has 18.84M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, RetinalGeniX Technologies Inc maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2.07, indicating conservative leverage, while an interest coverage ratio of -287.25 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -10,293.84, reflecting losses generated across the asset base.

As of the close on September 16, 2026, RetinalGeniX Technologies Inc's stock has gained approximately 12.71% over the past 52 weeks.

Over the twelve months ended June 30, 2026, RetinalGeniX Technologies Inc generated - - in revenue and converted that into -2.09M in net income, yielding earnings per share of -0.11. EBITDA reached -2.08M, while operating income came in at -2.08M.

As of June 30, 2026, RetinalGeniX Technologies Inc holds 27,232.00 in cash and equivalents against 54,596.00 in total debt, resulting in a net debt position of 21,768.00. Total book value stands at -2.64M, with working capital of -2.64M providing operational flexibility.

RetinalGeniX Technologies Inc produced -477,940.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.67, meaning RetinalGeniX Technologies Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, RetinalGeniX Technologies Inc has an Altman Z-Score of -1,109.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.